BNGO - Bionano jumps 36% as publication highlights optical genome mapping

• Life sciences company Bionano Genomics ( NASDAQ: BNGO ) added ~36% to reach an eight-month high on Thursday after the company announced the publication of a study highlighting the use of optical genome mapping (OGM) in the analysis of certain genetically-driven disorders.
• Bionano ( BNGO ) offers the Saphyr system that uses OGM to conduct genome analysis to detect genetic variation and function.
• The study published in Springer Link explains the use of OGM as an alternative to Southern blot, the gold standard method to detect repeat expansion disorders, a term used to classify a group of conditions caused by short tandem DNA repeats.
• According to the company, the study demonstrates the ability of OGM to replace the labor-intensive and time-consuming Southern blot.
• “We are optimistic that adding OGM to repeat expansion disorder research can potentially lead to better diagnosis for patients and more accurate data for neuroscience researchers,” Chief Executive of Bionano ( BNGO ) Erik Holmlin noted.

For further details see: